Company News » TIGIT, hFc, Human
TIGIT Fc Chimera, Human

Immobilized CD155 Fc, human (Cat.No.Z03435) at 5 μg/mL (100μL/well) can bind Biotin-TIGIT Fc, Human with a linear range of 6.1-48.8ng/mL.

TIGIT Fc Chimera, Human

Recombinant Human TIGIT Fc Chimera produced in HEK293 cells is a polypeptide chain containing 352 amino acids with the C-termimal human IgG1 Fc fragment. A fully biologically active molecule, rhTIGIT has a molecular mass of 50-55 kDa, analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.
Z03439
$250.00

Ask us a question
Product Introduction
Species Human
Protein Construction
TIGIT (Met22-Pro141)
Accession # Q495A1		 hFc
N-term C-term
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity Immobilized PVR/CD155, hFc, Human (Cat. No.: Z03435) at 5.0 μg/ml (100 µl/well) can bind biotinylated TIGIT, hFc, Human with a linear range of 6.1-48.83 ng/ml when detected by Streptavidin-HRP.
Expression System HEK 293
Apparent Molecular Weight 50~55 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, 5% trehalose and mannitol.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Examples
  • TIGIT Fc Chimera, Human
    • TIGIT Fc Chimera, Human

    Immobilized CD155 Fc, human (Cat.No.Z03435) at 5 μg/mL (100μL/well) can bind Biotin-TIGIT Fc, Human with a linear range of 6.1-48.8ng/mL.


Background
Target Background T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3). It belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). It binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells.
Synonyms TIGIT; VSIG9; VSTM3; WUCAM; T Cell Immunoreceptor with Ig and ITIM Domains

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.